Effects of flavophospholipol on conjugation and plasmid curing of multidrug-resistant Salmonella Enteritidis in broiler chickens

Kelvin Lim 1*, Michael Pennell 2, Stephanie Lewis 3, Mohamed El-Gazzar 4 and Wondwossen A. Gebreyes 5

1 Veterinary Health Management Branch, National Parks Board, 6 Perahu Road, Singapore 718827; 2 Division of Biostatistics, College of Public Health, The Ohio State University, 1841 Neil Ave, 246 Cunz Hall, Columbus, OH 43210, USA; 3 Animal Resource Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA; 4 Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, 2203 Lloyd Veterinary Medical Centre, Ames, IA 50011, USA; 5 Department of Veterinary Preventive Medicine, College of Veterinary Medicine, The Ohio State University, A100R Sisson Hall, 1920 Coffey Rd, Columbus, OH 43210, USA

*Corresponding author. E-mail: kelvin_lim@nparks.gov.sg

Received 8 December 2020; accepted 4 February 2021

Background: Early in vitro studies suggested that flavophospholipol has plasmid-curing effects and could inhibit conjugation by disrupting pilus formation between bacteria.

Objectives: This 36-day controlled-challenge study aimed to evaluate the anti-conjugative and plasmid-curing effect of flavophospholipol in vivo on plasmid-mediated antimicrobial resistance (AMR) in MDR transconjugant Salmonella Enteritidis in chickens.

Methods: A total of 270-day-old chicks were randomly assigned to four control and four treatment groups with two doses of in-feed flavophospholipol (10 ppm and 64 ppm) and in the presence and absence of ampicillin in drinking water. Chicks were orally challenged with Salmonella Enteritidis with known plasmid-encoded AMR factors. Cloacal swabs were collected on Day 7, 14 and 23. On Day 35, all chickens were euthanized, and caecal tissue and content were collected. Antimicrobial susceptibility testing was done with a panel of 12 antimicrobials and interpreted according to CLSI breakpoints.

Results: Flavophospholipol given in-feed at 64 ppm had an anti-conjugative effect. There was a significant reduction of acquisition of resistance to ampicillin, streptomycin and tetracycline by the recipient strains of Salmonella Enteritidis in treatment groups given flavophospholipol in-feed at 64 ppm (P < 0.05). This was not seen with flavophospholipol given in-feed at 10 ppm.

Conclusions: The results demonstrate that flavophospholipol given in-feed at 64 ppm had an anti-conjugative effect. The results also suggest that AMR is reduced through other mechanisms of action, which are yet to be determined. There is insufficient evidence that flavophospholipol at 64 ppm in feed alone or with subtherapeutic levels of antibiotics had a plasmid-curing effect.

Introduction

Flavophospholipol (also known as bambermycin or moenomyacin), is the first member of the bambermycin class of phosphoglycolipid antibiotics and exhibits bactericidal effects by inhibiting the transglycosylase activity of the penicillin-binding proteins and stopping bacterial cell wall synthesis. Flavophospholipol is primarily effective against Gram-positive bacteria, and Gram-negative bacteria such as salmonellae are only slightly susceptible. Flavophospholipol has no human therapeutic use and it has a positive effect on weight gain and feed conversion ratios in food animals. Early in vitro studies suggested that flavophospholipol has a ‘plasmid-curing’ effect on members of the family Enterobacteriaceae. In vitro studies also indicated that flavophospholipol could inhibit conjugation by disrupting the formation of the plasmid bridge (pili) between bacteria. Early in vivo studies showed flavophospholipol given in-feed could decrease resistance against ampicillin, tetracycline, streptomycin and/or sulphonamides in faecal Escherichia coli and/or salmonellae. However, the anti-conjugative or plasmid-curing mechanisms of action are not evident in past studies. There is a paucity of experimental trials validating the results in vivo in food animals using MDR Salmonella.
Salmonella infection is a significant global public health issue, responsible for an estimated 93.8 million illnesses and 155,000 deaths annually worldwide and 1 million foodborne illnesses and more than 350 deaths annually in the United States. Poultry and contaminated poultry products are among the most frequently implicated sources. MDR Salmonella exacerbates the problem and is associated with more invasive and severe disease in humans. Some MDR Salmonella strains with extensive resistance profiles (e.g., MDR Salmonella Typhimurium DT104) pose greater threats to public health and have been associated with higher mortality and morbidity rates. Conjugative plasmids facilitate the movement of antimicrobial resistance (AMR) genes in different Enterobacteriaceae, including Salmonella. The use of agents that would not be allowed in human therapy and could be used to select against AMR, such as flavophospholipol, is therefore an issue of interest.

The study had two aims. The first was to determine whether flavophospholipol given in-feed at 10 ppm and 64 ppm doses could reduce conjugation of plasmid-mediated MDR S. Enteritidis in vivo in the broiler chicken model. The second aim was to determine if flavophospholipol given in-feed at 10 ppm and 64 ppm alone and in the presence of subtherapeutic levels of antimicrobials would have a plasmid-curing effect. Flavophospholipol 10 ppm is the average recommended dose and it has been demonstrated that 64 ppm could be used in broiler chickens safely.

Materials and methods

Salmonella Enteritidis recipient and donor strains

One recipient and two donor S. Enteritidis strains were used in the study. The donor strain, DS1 is an R-type (AmClAxChStTeSuCpNa) that exhibits resistance to ampicillin, chloramphenicol, amoxicillin/clavulanic acid, cephalothin, streptomycin, tetracycline, sulfisoxazole, ceftriaxone and cefixime. The recipient strain (RS) is resistant to nalidixic acid only. A second donor strain DS2, used to test plasmid-curing, is a transconjugant (AmAxChStTeSuCpNa) that exhibits resistance to ampicillin, chloramphenicol, amoxicillin/clavulanic acid, cephalothin, streptomycin, tetracycline, sulfisoxazole, ciprofloxacin and nalidixic acid. The donor strain was a human-outbreak field isolate from the USA and the recipient strain was an environmental field isolate from Ethiopia. The MICs of selected antimicrobials for the RS and DS1 strain, as confirmed using Sensititre Gram-negative MIC plates, are shown in Table 1. Growth of mentioned strains of S. Enteritidis was tested on LB selective agar plates containing 128 ppm of flavophospholipol.

Conjugation assay in vitro

Conjugation experiments (using previously described procedures) were performed to determine whether resistance markers were located on conjugative plasmids. Briefly, DS1 was mated with a spontaneous rifampicin-resistant, ampicillin-susceptible E. coli K-12 strain MG1655 on LB agar and incubated at 37°C for 6 h. The mixture was then transferred to a selective LB plate containing rifampicin and ampicillin and incubated at 37°C for 24 h. Transconjugants were purified and confirmed to be E. coli instead of spontaneous mutants of rifampicin-resistant S. Enteritidis by culturing on MacConkey agar. The second donor strain, DS2 was a transconjugant derived from conjugating DS1 and RS.

Preparation of Salmonella Enteritidis challenge inocula

The three challenge strains (DS1, DS2 and RS) were plated onto Luria-Bertani agar (Becton Dickinson and Company, Sparks, MD, USA) and incubated at 37°C for 24 h. Growth curves were constructed for the three strains to determine the point at which cultures reached logarithmic growth. A colony from each strain was selected and transferred to three sets of 25 mL of LB broth and incubated in a shaker bath at 37°C for 4 h. Concentrations of challenge bacterial broths were adjusted to an optical density reading of 0.1 at OD600 with a spectrophotometer (GENESYS TM 20, Thermo Scientific, USA) which correlated to approximately 10^7 cfu/mL of Salmonella, and 1.5 at OD600, which correlated to approximately 10^9 cfu/mL of Salmonella. The concentrations of inoculum desired to test anti-conjugative effects of flavophospholipol were 10^7 and 10^9 cfu/mL for the donor and recipient strains of S. Enteritidis, respectively. Challenge concentrations were adjusted to 10^9 cfu/mL for the strain used to test plasmid-curing effects of flavophospholipol. This is summarized in Table 2. Suspension concentrations were based on previous successful in vivo colonization and conjugation experiments involving E. coli in broiler chickens.

Animals and housing facilities

A total of 270 female Cobb × Ross day-old chicks were obtained from two commercial local hatcheries, which are participants of the National Poultry Improvement Plan (NPIP), USA. Feed, litter and faecal samples were tested on day 0 to confirm freedom from salmonellae. Chicks were distributed and housed in 90 three-tiered cages in three separate treatment rooms with similar conditions in an approved BSL-2 animal facility in Sisson Hall, The Ohio State University. There was no direct physical contact between chicks in different cages and personal protective equipment was provided for personnel prior to entering the rooms. Chicks were given ad libitum access to water and a stipulated amount of feed

Table 1. MICs (mg/L) of antimicrobial agents for donor and recipient strains of Salmonella Enteritidis used in in vitro and in vivo experiments

| Strain  | FOX | AZM | CHL | TET | CRO | AMC | CIP | GEN | NAL | CTF | SUF | SXT | AMP | STR |
|---------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Donor   | >32 | 4   | >32 | >32 | 16  | >32/16 | ≤0.015 | 0.5 | 4   | >8  | >256 | ≤0.12/2.38 | >32 | >64 |
| Recipient | 2   | 8   | 4   | ≤4  | ≤0.25 | 1/0.5 | 0.25  | ≤0.25 | >32 | 1   | 64  | >4/76 | 1   | 2   |

FOX, cefoxitin; AZM, azithromycin; CHL, chloramphenicol; TET, tetracycline; CRO, ceftriaxone; AMC, amoxicillin/clavulanic acid 2:1 ratio; CIP, ciprofloxacin; GEN, gentamicin; NAL, nalidixic acid; CTF, cefixime; SUF, sulfisoxazole; SXT, trimethoprim/sulfamethoxazole; AMP, ampicillin; STR, streptomycin.
Intervention

FDA-approved Flavomycin 4

Flavophospholipol was supplied as the commercially available, pholipol, 10 ppm or 64 ppm from day 0 to the end of study.

with different flavophospholipol interventions: no flavophospholipol, flavophospholipol (10 ppm feed) or flavophospholipol (64 ppm feed) + ampicillin in water

Chicks in treatment groups 5–8 received 0.5 mL of the DS2 transconjugant strain DS1, and 0.25 mL of the recipient strain RS while the chicks in treatment groups 1–4 received 0.25 mL of the donor strain DS1, and 0.25 mL of the recipient strain, RS while the chicks in treatment groups 5–8 were used for the testing the plasmid curing effects.

On day 3, chicks in treatment groups 1–4 received 0.25 mL of the DS2 transconjugant strain via oral gavage.

In vivo experimental design

Chicks were introduced into the 36 day study on day 0 and distributed into eight treatment groups (Table 2). Treatment groups 1–4 were used for testing the anti-conjugative effects and treatment groups 5–8 were used for the testing the plasmid curing effects.

On day 3, chicks in treatment groups 1–4 received 0.25 mL of the donor strain DS1, and 0.25 mL of the recipient strain, RS while the chicks in treatment groups 5–8 received 0.5 mL of the DS2 transconjugant strain via oral gavage.

The eight treatment groups received one of three diets with different flavophospholipol interventions: no flavophospholipol, 10 ppm or 64 ppm from day 0 to the end of study.

Flavophospholipol was supplied as the commercially available, FDA-approved Flavomycin 4° (Huvepharma®, NADA #44-759). Flavomycin contains the active ingredient (flavophospholipol) at a concentration of 8.8 g/kg (4 g/lb). The feed was mixed in-house in accordance with the manufacturer's instructions. Subtherapeutic levels of ampicillin were given in water to treatment groups 4, 6 and 8 for 12 days to test the application of selective pressure and promotion of AMR. Chickens were provided 100 mg/kg of live body weight or half doses of ampicillin for 12 days from day 10 to 21.

Doses were prepared for an average of 270 g in live body weight from day 10 to 15 and 650 g in live body weight from day 16 to 21. Stock solutions were made from ampicillin trihydrate (Fisher Scientific, USA) and diluted to the required concentrations. Fresh solutions were prepared for the treatment groups daily.2

Cloacal samples were collected at 4, 11 and 20 days post inoculation (p.i.) and caecal samples from euthanized chickens were collected at the end of the study (32 days p.i.).

Bacteriological methods

Salmonella was isolated by conventional methods.16 Briefly, samples were placed in buffered peptone water (Becton Dickinson and Company, Sparks, MD, USA) at approximately 1:10 ratio and incubated at 37°C for 24 h. An aliquot of 100 µL of the broth was transferred to 9.9 mL of Rappaport-Vassiliadis broth (Oxoid, Hants, England) and incubated for 18 to 24 h at 42°C. The broth was streaked onto selective Xylose-Lysine-Tergitol 4 (XLT4) agar plates (Becton Dickinson and Company, Sparks, MD, USA) with and without antibiotics and incubated for 18 to 24 h. All antibiotic stocks used for the making of XLT4 plates with antibiotics were prepared according to manufacturer's specifications (Sigma Aldrich, St Louis, MO, USA). Samples from chickens in treatment groups 1–4 were streaked on selective XLT4 agar plates containing 100 ppm ampicillin and 30 ppm nalidixic acid to select for transconjugants which were naturally resistant to nalidixic acid and acquired resistance to ampicillin. Samples from chickens in treatment groups 5–8 were streaked on selective XLT4 agar plates with 30 ppm nalidixic acid to select for nalidixic acid-resistant transconjugants. Up to three colonies per positive sample were isolated and cryopreserved for phenotypic characterization. Conjugation events between donor and recipient strains were only confirmed in chickens in treatment groups 1–4 if transconjugant salmonellae could be isolated from their cloacal or caecal samples.

Antimicrobial susceptibility testing

Antimicrobial susceptibility testing was done with a panel of 12 antimicrobials using the Kirby-Bauer method.17 The following are the BD BBL™ Sensi-Disc™ (Becton Dickinson and Company,
Sparks, MD, USA) antimicrobial susceptibility test discs used with their respective disc potencies: ampicillin (Am, $10\mu g$), tetracycline (Te, $30\mu g$), ceftiofur (XNL, $30\mu g$), chloramphenicol (C, $30\mu g$), sulfisoxazole (G, $250\mu g$), streptomycin (S, $10\mu g$), kanamycin (K, $30\mu g$), gentamicin (CN, $10\mu g$), ceftriaxone (CRO, $30\mu g$), ciprofloxacin (CIP, $5\mu g$), cephalothin (KF, $30\mu g$) and amoxicillin/clavulanic acid (AmpC) discs at $10\mu g$.

Figure 1. PFGE dendrogram of DS, RS1, RS2 and selected isolates from treatment groups. The selected isolates were clonally related to the challenge strains and no other extraneous salmonellae were detected.
acid (AMC, 30 μg). Zone diameter sizes were evaluated according to CLSI breakpoints. *E. coli* ATCC 25922, *Enterococcus faecalis* ATCC 29212, *Staphylococcus aureus* ATCC 25923 and *Pseudomonas aeruginosa* ATCC 27853 were used as quality control organisms.

**Molecular analysis**

PFGE was performed on DS1, DS2, and RS to determine if the isolates were from the challenge strains or any extraneous *Salmonella* introduced during the study. At each timepoint, we randomly selected two isolates (from two different chickens) per group for analysis. PFGE was performed according to CDC’s PulseNet protocol.18 DNA was digested with 50 U of XbaI restriction enzyme (New England Biolabs, Ipswich, MA, USA) for at least 2 h at 37°C. *Salmonella Braenderup H9812* was used as a molecular reference marker. Electrophoresis was performed using CHEF-DR III Pulsed-Field Electrophoresis System (Bio-Rad Laboratories, Hercules, CA, USA) with the following conditions and reagents: 1% Seakem Gold agarose (FMC BioProducts, Rockland, Maine, USA) in 0.5% Tris-borate EDTA buffer, temperature: 14°C; voltage: 6 V/cm; run time: 18 h with switch times ranging from 2.2 to 63.8 s. The gels were stained with ethidium bromide and the DNA bands were visualized under UV trans-illumination (Gel DocTM 2000, Bio-Rad Laboratories, Hercules, CA, USA) and gel images were captured using the Quantity one 1-D analysis software (Bio-Rad Laboratories, Hercules, CA, USA). PFGE gels were consolidated and visualized using Bionumerics software V. 4.61 (Applied Maths NV, Belgium).

**Statistical analysis**

The statistical software used was Intercooled STATA 12 (StataCorp, College Station, TX). Correlation of observations of chickens within a cage were accounted for in analyses and sample size determinations. Sample size calculations were made using the module ‘clustersamps’.19 It was assumed that 80% of isolates in poultry would be resistant post-inoculation as studies in organic and conventional broiler farms show that resistance ranged from 55.2% to 91.4%.20 An absolute decrease of 50% was assumed based on earlier studies of flavophospholipol showing that it significantly reduced the detection of *Salmonella* with MDR phenotypes by about 40%6 and the mean degree of ampicillin resistance in *E. coli* by about 64%.3 To detect an absolute decrease of 50% in AMR with 80% power, with a significance level of 5%, and assuming a fixed number of three chickens per cage, 30 chickens per intervention group were required. Allowing for a 10% mortality rate in chickens, we planned for 33 chickens per intervention group except for the control group 1, which had 39 chickens to account for additional mortalities due to the absence of flavophospholipol. The sample size calculation assumed an Intracluster Correlation (ICC) of 0.5–0.6 based on previous estimates of ICC in AMR of isolates from the same animal.21 This is a conservative estimate of the ICC for our study since we expect within-cage ICCs to be smaller than within-chicken ICCs. A *P* value <0.05 was considered statistically significant.

Differences in the proportions of chickens testing positive for transconjugant salmonella among groups 1–4 were assessed using logistic regression with robust standard errors accounting for within-cage relationships [vce (cluster) option in the logistic command in STATA22]. Separate models were fit to data at each timepoint and Bonferroni corrections were used to control the overall type-I error rate across pairwise comparisons of treatment groups. Differences in proportions of nalidixic acid-resistant salmonellae that either retained or lost ampicillin resistance (binary variable) among groups 5–8 were also assessed using logistic regression with robust standard errors.

**Results**

A total of 2137 *Salmonella* isolates were tested for antimicrobial susceptibility and 66 isolates showed changes in AMR profiles.
The 66 isolates along with the three challenge strains were collected and processed for DNA fingerprinting by PFGE to determine clonality of the isolates (Figure 1). There were no significant acquisitions of resistances to chloramphenicol, gentamicin and kanamycin by the recipient strain (RS) and transconjugant strain (DS2). The differences in resistances to the following antimicrobials were assessed in detail: ampicillin, streptomycin, tetracycline, ceftriaxone and ceftiofur.

The 66 isolates along with the three challenge strains were collected and processed for DNA fingerprinting by PFGE to determine clonality of the isolates (Figure 1). There were no significant acquisitions of resistances to chloramphenicol, gentamicin and kanamycin by the recipient strain (RS) and transconjugant strain (DS2). The differences in resistances to the following antimicrobials were assessed in detail: ampicillin, streptomycin, tetracycline, ceftriaxone and ceftiofur.

### Table 3. Numbers and OR of chickens which tested positive (R+) and tested negative (R−) for ampicillin-resistant transconjugant salmonellae

| Timepoint | Treatment     | R− | R+  | % R+  | OR (95% CI)          | Bonferroni corrected P value |
|-----------|---------------|----|-----|-------|----------------------|-----------------------------|
| 4 days p.i. | Control      | 27 | 9   | 25.0  | reference            |                             |
|           | Flavo-10 ppm | 19 | 13  | 40.6  | 2.05 (0.65–6.53)     | 1.000                       |
|           | Flavo-64 ppm | 31 | 1   | 3.1   | 0.10 (0.01–0.77)     | 0.243                       |
|           | Ampicillin   | 17 | 12  | 41.4  | 2.12 (0.61–7.36)     | 1.000                       |
| 11 days p.i. | Control     | 14 | 21  | 60.0  | reference            |                             |
|           | Flavo-10 ppm | 18 | 14  | 43.8  | 0.52 (0.17–1.60)     | 1.000                       |
|           | Flavo-64 ppm | 24 | 6   | 20.0  | 0.17 (0.05–0.56)     | 0.036                       |
|           | Ampicillin   | 14 | 13  | 48.1  | 0.62 (0.19–2.00)     | 1.000                       |
| 20 days p.i. | Control     | 11 | 21  | 69.0  | reference            |                             |
|           | Flavo-10 ppm | 10 | 22  | 68.8  | 1.15 (0.37–3.56)     | 1.000                       |
|           | Flavo-64 ppm | 20 | 8   | 28.6  | 0.21 (0.06–0.76)     | 0.162                       |
|           | Ampicillin   | 6  | 22  | 78.6  | 1.92 (0.43–8.56)     | 1.000                       |
| 32 days p.i. | Control     | 0  | 32  | 100.0 | reference            |                             |
|           | Flavo-10 ppm | 2  | 30  | 93.8  | 0.43 (0–5.66)        | 1.000 (exact)               |
|           | Flavo-64 ppm | 5  | 23  | 82.1  | 0.35 (0–0.97)        | 0.064 (exact)               |
|           | Ampicillin   | 0  | 27  | 100   | –                    | –                            |

Robust standard errors (SEs), accounting for cage clustering were used. Bonferroni correction of 9 was used for comparisons of swab results (3 time-points × 3 treatments compared with control) and a correction of 3 was used to compare caecum results at 32 days p.i. (3 treatments compared with control). Exact logistic regression models were used where (exact) is indicated.

![Figure 3. Proportion of ampicillin-resistant transconjugant salmonellae isolated from treatment groups 1–4 that were also resistant to streptomycin.](https://academic.oup.com/jacamr/article/3/1/dlab022/6168032/)

The proportion of chickens that tested positive for ampicillin-resistant salmonellae in treatment groups 1–4 are shown in Figure 2 and Table 3. A greater proportion of chickens in the control group had ampicillin-resistant isolates than in treatment group 3.

**Lower numbers of chickens with ampicillin-resistant salmonellae were observed in Treatment Group 3 (flavophospholipol 64 ppm)**

The proportion of chickens that tested positive for ampicillin-resistant salmonellae in treatment groups 1–4 are shown in Figure 2 and Table 3. A greater proportion of chickens in the control group had ampicillin-resistant isolates than in treatment group 3.
at 11 days p.i. (OR 5.99, 95% CI 1.79–20.00, P = 0.036). There were no observable differences in the number of chickens that tested positive for ampicillin-resistant transconjugants between the control group and treatment group 4, which was given sub-therapeutic levels of ampicillin.

Reduced acquisition of resistance to streptomycin and tetracycline by salmonellae in Treatment Group 3 (flavophospholipol 64 ppm)

Streptomycin and tetracycline resistance in ampicillin-resistant salmonellae isolated from treatment groups 1–4 are shown in Figure 3 and Figure 4, and Table 4 and Table 5, respectively. Reduced acquisition of resistance to streptomycin and tetracycline in treatment group 3 as compared with the control was observed at 11, 20 and 32 days p.i., although this reduction was not statistically significant. The resistance pattern of the transconjugants to streptomycin and tetracycline in treatment group 2 was similar to that in the control. There were no observable differences in extended-spectrum cephalosporin resistance (ESC-R) in isolates between each treatment and control group (data not shown).

No loss of resistance in MDR salmonellae in chickens given in-feed flavophospholipol alone and with sub-therapeutic levels of ampicillin

The prevalence and associated loss of plasmid-mediated ampicillin resistance did not differ between treatment groups 5–8

---

**Table 4. Proportion of streptomycin-resistant transconjugants in treatment groups 1–4**

| Timepoint | Treatment | R- | R+ | % R+ |
|-----------|-----------|----|----|------|
| 4 days p.i. | 1. Control | 17 | 0  | 0    |
|           | 2. Flavo-10 ppm | 23 | 0  | 0    |
|           | 3. Flavo-64 ppm | 19 | 7   | 26.9 |
|           | 4. Ampicillin | 10 | 3  | 23.1 |
| 11 days p.i. | 1. Control | 21 | 38 | 64.4 |
|           | 2. Flavo-10 ppm | 6  | 18 | 75.0 |
|           | 3. Flavo-64 ppm | 10 | 3  | 23.1 |
|           | 4. Ampicillin | 11 | 24 | 68.6 |
| 20 days p.i. | 1. Control | 9  | 44 | 83.0 |
|           | 2. Flavo-10 ppm | 18 | 36 | 66.7 |
|           | 3. Flavo-64 ppm | 8  | 14 | 63.6 |
|           | 4. Ampicillin | 8  | 52 | 86.7 |
| 32 days p.i. | 1. Control | 22 | 66 | 75.0 |
|           | 2. Flavo-10 ppm | 26 | 62 | 70.5 |
|           | 3. Flavo-64 ppm | 32 | 38 | 54.3 |
|           | 4. Ampicillin | 19 | 56 | 74.7 |

R, streptomycin resistance.

**Table 5. Proportion of tetracycline-resistant transconjugants in treatment groups 1–4**

| Timepoint | Treatment | R- | R+ | % R+ |
|-----------|-----------|----|----|------|
| 4 days p.i. | 1. Control | 17 | 0  | 0    |
|           | 2. Flavo-10 ppm | 23 | 0  | 0    |
|           | 3. Flavo-64 ppm | 0  | 1  | 100.0 |
|           | 4. Ampicillin | 18 | 8   | 38.0 |
| 11 days p.i. | 1. Control | 19 | 40 | 67.8 |
|           | 2. Flavo-10 ppm | 6  | 18 | 75.0 |
|           | 3. Flavo-64 ppm | 10 | 3  | 23.1 |
|           | 4. Ampicillin | 9  | 26 | 74.3 |
| 20 days p.i. | 1. Control | 7  | 46 | 86.8 |
|           | 2. Flavo-10 ppm | 19 | 35 | 64.8 |
|           | 3. Flavo-64 ppm | 8  | 14 | 63.6 |
|           | 4. Ampicillin | 8  | 52 | 86.7 |
| 32 days p.i. | 1. Control | 23 | 65 | 73.9 |
|           | 2. Flavo-10 ppm | 25 | 63 | 71.6 |
|           | 3. Flavo-64 ppm | 29 | 41 | 58.6 |
|           | 4. Ampicillin | 18 | 57 | 76.0 |

R, tetracycline resistance.
There were no clear, observable differences in resistances to streptomycin and tetracycline (data not shown).

Reduced acquisition of resistance to third-generation cephalosporins with in-feed flavophospholipol 64 ppm

A higher proportion of chickens with ESC-R transconjugant salmonellae in the control group was observed compared with treatment group 8 (flavophospholipol 64 ppm and ampicillin) at 20 days p.i. (OR 2.40, 95% CI 1.25 to $\infty$, $P = 0.053$) (Figure 6 and Table 7). A significantly higher proportion of chickens with ESC-R transconjugant salmonellae were recovered in the control group as compared with treatment group 7 (flavophospholipol 64 ppm) at 32 days p.i. (OR 16.67, 95% CI 2.02–142.86, $P = 0.027$) and as compared with treatment group 8 at 32 days p.i. (OR 2.84, 95% CI 1.50 to $\infty$, $P = 0.0009$). This was indicative of reduced acquisition of ESC-R by DS2 in chickens in groups given in-feed flavophospholipol 64 ppm.

The proportion of nalidixic acid-resistant transconjugant salmonellae that acquired resistance to ceftriaxone and cefotiofur across treatment groups 5–8 is shown in Figure 7 and Figure 8 and Table 8 and Table 9, respectively. Significantly greater proportions of ESC-R nalidixic acid-resistant salmonellae were recovered from the control group as compared with those from treatment group 7 at 20 days p.i. (OR 24.39, 95% CI 2.86–208.33, $P = 0.027$) and 32 days p.i. (OR 15.15, 95% CI 2.00–114.9, $P = 0.027$). Similarly, greater proportions of nalidixic acid-resistant salmonellae recovered from control group 5 were ESC-R as compared with those from treatment group 8 at the 20 days p.i. (OR 3.33, 95% CI 1.81 to $\infty$, $P < 0.0001$) and at 32 days p.i. timepoints (OR 3.57, 95% CI 1.96 to $\infty$, $P < 0.0001$).

Discussion

Ampicillin-resistant Salmonella transconjugants that resulted from in vivo conjugation were recovered from treatment groups 1–4. There were significantly reduced numbers of chickens that tested positive for ampicillin-resistant transconjugant salmonellae in treatment group 3 (flavophospholipol 64 ppm) as compared with the control group 1 across time, indicative of reduced acquisition of ampicillin resistance in chickens given flavophospholipol 64 ppm. Anti-conjugative effects were significant at 11 days p.i. and marginally significant at 32 days p.i. Results were similar but not significant at 4 and 20 days p.i. The findings in this study indicated that the use of in-feed flavophospholipol at 64 ppm resulted in the reduction of conjugation events. This is consistent with previously hypothesized anti-conjugative effects of flavophospholipol, but the effect was only seen with flavophospholipol given at higher than the recommended dose of 10 mg/kg. Further studies to determine dose–response relationships and the effects of graduated doses of flavophospholipol and its anti-conjugative effects would be needed to determine the ideal concentration to achieve maximum effect.

Streptomycin and tetracycline resistance was not determined in vitro to be carried on conjugative plasmids prior to the study. However, the ampicillin-resistant transconjugants recovered in treatment groups 1–4 had also acquired resistance to tetracycline and streptomycin. There was reduced resistance to streptomycin and tetracycline in the treatment group given flavophospholipol in-feed at 64 ppm compared with the control. While inconclusive on its own, this finding suggests that transconjugant salmonellae in chickens in treatment group 3 did not acquire resistance to streptomycin and tetracycline at the same rate as that in the control group.
The loss of plasmid-mediated ampicillin resistance or plasmid curing was not significant with the addition of flavophospholipol in-feed at 64 ppm alone or with subtherapeutic levels of ampicillin in groups 5–8. A significant observation was that the transconjugants in treatment groups 5–8 unexpectedly acquired ESC-R. While poultry production rarely uses cephalosporin treatments, broiler chickens could harbour ESBL or pAmpC-producing E. coli. These chickens could be colonized with commensal bacteria or E. coli harbouring plasmids conferring resistance to extended-spectrum cephalosporins. This was not evident in groups 1–4 due to possible co-selection of other antibiotic resistance such as β-lactams.

### Table 6. Comparison of ampicillin-resistant transconjugants in treatment groups 6–8 versus control group 5

| Timepoint       | Treatment          | R- | R+ | % R+ | OR (95% CI) | Bonferroni corrected P value |
|-----------------|--------------------|----|----|------|-------------|-----------------------------|
| 4 days p.i.     | 5. Control         | 2  | 80 | 97.6 | reference   | -                           |
|                 | 6. Flavo-10 ppm + AMP | 2  | 90 | 97.8 | 1.13 (0.20–6.26) | 1.000                      |
|                 | 7. Flavo-64 ppm    | 5  | 85 | 94.4 | 0.43 (0.11–1.62) | 1.000                      |
|                 | 8. Flavo-64 ppm + AMP | 4  | 93 | 95.9 | 0.58 (0.12–2.82) | 1.000                      |
| 11 days p.i.    | 5. Control         | 2  | 78 | 97.5 | reference   | -                           |
|                 | 6. Flavo-10 ppm + AMP | 0  | 95 | 100.0 | 2.89 (0.22 to ∞) | 1.000 (exact)             |
|                 | 7. Flavo-64 ppm    | 3  | 73 | 96.1 | 0.62 (0.13–3.09) | 1.000                      |
|                 | 8. Flavo-64 ppm + AMP | 0  | 98 | 100.0 | 1.44 (0.61 to ∞) | 1.000 (exact)             |
| 20 days p.i.    | 5. Control         | 3  | 77 | 96.3 | reference   | -                           |
|                 | 6. Flavo-10 ppm + AMP | 0  | 91 | 100.0 | 4.47 (0.47 to ∞) | 0.900 (exact)             |
|                 | 7. Flavo-64 ppm    | 9  | 77 | 89.5 | 0.33 (0.08–1.37) | 1.000                      |
|                 | 8. Flavo-64 ppm + AMP | 1  | 89 | 98.9 | 3.47 (0.39–31.08) | 1.000                      |
| 32 days p.i.    | 5. Control         | 6  | 78 | 92.9 | reference   | -                           |
|                 | 6. Flavo-10 ppm + AMP | 2  | 96 | 98.0 | 3.69 (0.47–28.71) | 0.636                      |
|                 | 7. Flavo-64 ppm    | 7  | 86 | 92.5 | 0.95 (0.31–2.88) | 1.000                      |
|                 | 8. Flavo-64 ppm + AMP | 2  | 92 | 97.9 | 3.54 (0.82–15.26) | 0.270                      |

R, ampicillin resistance; AMP, ampicillin. Robust standard errors (SEs), accounting for cage clustering were used. A Bonferroni correction of 9 was used for timepoints 4, 11 and 20 days post inoculation, to control errors introduced in pair-wise tests comparing swab results in 3 treatment groups and control, and a Bonferroni correction of 3 was applied at timepoint 32 days post inoculation, to control errors introduced in pair-wise tests comparing caecum results in 3 treatment groups and control. Exact logistic regression models were used where (exact) is indicated.

Figure 6. Proportion of chickens in treatment groups 5–8 from which transconjugant salmonellae resistant to extended-spectrum cephalosporins were recovered. Key: *; proportions that were marginally significantly different from the control (P < 0.1); **; proportions that were significantly different from the control (P < 0.05).
as streptomycin or tetracycline, associated with the transfer of other mobile genetic elements.  

When we compared the proportion of chickens in treatment groups 5–8 that tested positive for ESC-R transconjugants, a significantly greater proportion of chickens in control group 5 tested positive for these transconjugants than in treatment groups 7 and 8 at various timepoints. None of the isolates in treatment group 8 (flavophospholipol 64 ppm and ampicillin) displayed ESC-R. Flavophospholipol reduces the acquisition of ESC-R.  

There was insufficient evidence to determine whether subtherapeutic doses of ampicillin increased conjugation events in the chicken gut. It is likely that long-term and low-level exposures to antimicrobials would exert selection pressure as opposed to short-term, full or subtherapeutic dosing. Thus, the impact of subtherapeutic levels of ampicillin is more observable in a commercial poultry farm setting, with multiple production cycles. The transconjugants isolated across all treatment groups and times exhibited phenotypes with multiresistance. A majority

| Timepoint | Treatment          | R− | R+ | % R+ | OR (95% CI) | Bonferroni corrected P value |
|-----------|--------------------|----|----|------|-------------|-----------------------------|
| 4 days p.i. | 5. Control        | 29 | 0  | 0    |             | reference                  |
|           | 6. Flavo-10 ppm + AMP | 27 | 5  | 15.6 | 6.84 (0.88-∞) | 0.4842 (exact) |
|           | 7. Flavo-64 ppm    | 32 | 0  | 0    |             |                             |
|           | 8. Flavo-64 ppm + AMP | 34 | 0  | 0    |             |                             |
| 11 days p.i. | 5. Control        | 23 | 5  | 17.9 |             | reference                  |
|           | 6. Flavo-10 ppm + AMP | 26 | 6  | 18.8 | 1.06 (0.19-5.92) | 1.000 |
|           | 7. Flavo-64 ppm    | 21 | 5  | 19.2 | 1.10 (0.29-4.12) | 1.000 |
|           | 8. Flavo-64 ppm + AMP | 32 | 0  | 0    | 0.48 (0-0.96) | 0.324 (exact) |
| 20 days p.i. | 5. Control        | 20 | 7  | 25.9 |             | reference                  |
|           | 6. Flavo-10 ppm + AMP | 23 | 9  | 28.1 | 1.12 (0.29-4.26) | 1.000 |
|           | 7. Flavo-64 ppm    | 29 | 1  | 3.3  | 0.10 (0.01-0.80) | 0.279 |
|           | 8. Flavo-64 ppm + AMP | 31 | 0  | 0    | 0.42 (0-0.80) | 0.053 (exact) |
| 32 days p.i. | 5. Control        | 18 | 10 | 35.7 |             | reference                  |
|           | 6. Flavo-10 ppm + AMP | 26 | 7  | 21.2 | 0.48 (0.08-2.82) | 1.000 |
|           | 7. Flavo-64 ppm    | 30 | 1  | 3.2  | 0.06 (0.01-0.80) | 0.027 |
|           | 8. Flavo-64 ppm + AMP | 32 | 0  | 0    | 0.35 (0-0.67) | 0.0009 (exact) |

AMP, ampicillin. Robust standard errors (SEs), accounting for cage clustering were used. A Bonferroni correction of 9 was used for timepoints 4, 11 and 20 days post inoculation, to control errors introduced in pair-wise tests comparing swab results in 3 treatment groups and control, and a Bonferroni correction of 3 was applied at timepoint 32 days post inoculation, to control errors introduced in pair-wise tests comparing caecum results in 3 treatment groups and control. Exact logistic regression models were used where (exact) is indicated.

Figure 7. Proportion of transconjugants in treatment groups 5–8 which were resistant to ceftriaxone. Key: *, proportions that were marginally significantly different from the control (P < 0.1); **, proportions that were significantly different from the control (P < 0.05).
acquired resistance to cephalothin, a first-generation cephalosporin antibiotic, and amoxicillin/clavulanic acid. This was previously suggested to be caused by an over-expression of the bla<sub>PSE1</sub> gene, which encodes resistance to ampicillin and amoxicillin/clavulanic acid.\textsuperscript{25} As the majority of transconjugants were resistant to ampicillin, cross-resistance to cephalothin and amoxicillin/clavulanic acid is expected. Acquisition of ciprofloxacin resistance in the transconjugants is also observed. This could be due to an associated nalidixic acid resistance, which is mediated by quinolone resistance-determining regions of gyrA.\textsuperscript{26}

Only ampicillin resistance was confirmed to be carried on a conjugative plasmid prior to the study. Additional steps are needed to determine whether resistance to streptomycin, tetracycline and extended-spectrum cephalosporins are plasmid-mediated. Flavophospholipol could alter the microbiome or bacterial community of the chicken gut to a state that is not ideal for the transfer of resistance genes. Further studies are required to investigate the potential anti-conjugative and plasmid-curing effect of flavophospholipol.

Table 8. Proportions and odds of ceftriaxone-resistant transconjugants in treatment groups 6–8 versus control group 5, accounting for cage clustering

| Timepoint      | Treatment                  | R− | R+ | % R+ | OR (95% CI) | Bonferroni corrected P value |
|----------------|----------------------------|----|----|-------|-------------|-----------------------------|
| 4 days p.i.    | 5. Control                 | 82 | 0  | 0.0   | reference   | –                           |
|                | 6. Flavo-10 ppm + AMP      | 79 | 13 | 14.1  | 18.57 (3.01 to ∞) | 0.0027 (exact) |
|                | 7. Flavo-64 ppm            | 90 | 0  | 0.0   |             | –                           |
|                | 8. Flavo-64 ppm + AMP      | 97 | 0  | 0.0   |             | –                           |
| 11 days p.i.   | 5. Control                 | 73 | 7  | 8.8   | reference   | –                           |
|                | 6. Flavo-10 ppm + AMP      | 78 | 17 | 17.9  | 2.27 (0.41–12.46) | 1.000                        |
|                | 7. Flavo-64 ppm            | 70 | 6  | 7.9   | 0.89 (0.25–3.20) | 1.000                        |
|                | 8. Flavo-64 ppm + AMP      | 98 | 0  | 0.0   | 0.43 (0.0–0.81) | 0.0576 (exact) |
| 20 days p.i.   | 5. Control                 | 62 | 18 | 22.5  | reference   | –                           |
|                | 6. Flavo-10 ppm + AMP      | 70 | 21 | 23.1  | 1.03 (0.26–4.13) | 1.000                        |
|                | 7. Flavo-64 ppm            | 85 | 1  | 1.2   | 0.04 (0.0048–0.35) | 0.027                        |
|                | 8. Flavo-64 ppm + AMP      | 90 | 0  | 0.0   | 0.30 (0–0.55) | <0.0001 (exact) |
| 32 days p.i.   | 5. Control                 | 63 | 21 | 25.0  | reference   | –                           |
|                | 6. Flavo-10 ppm + AMP      | 81 | 17 | 17.3  | 0.63 (0.13–3.09) | 1.000                        |
|                | 7. Flavo-64 ppm            | 91 | 2  | 2.2   | 0.07 (0.0087–0.50) | 0.027                        |
|                | 8. Flavo-64 ppm + AMP      | 94 | 0  | 0.0   | 0.28 (0–0.51) | <0.0001 (exact) |

R, ceftriaxone resistance; AMP, ampicillin. Robust SEs, accounting for cage clustering were used for timepoints 4, 11 and 20 days post inoculation (p.i.). A Bonferroni correction of 9 was used for these timepoints, to control errors introduced in pair-wise tests comparing swab results in 3 treatment groups and control, and a Bonferroni correction of 3 was applied at timepoint 32 days p.i., to control errors introduced in pair-wise tests comparing caecum results in 3 treatment groups and control. Exact logistics regression models were used where (exact) is indicated.
resistance between bacteria or which promotes the excretion of MDR bacteria. Plasmid profile analysis of *Salmonella* isolates from the study and metagenomic studies of the gut of chickens in different intervention groups would be useful. Further *in vivo* studies to determine dose–response relationships of flavophospholipol will be helpful to determine an ideal concentration for animal production.

**Conclusions**

This study has shown that flavophospholipol given in-feed at 64 ppm has anti-conjugative effects *in vivo* in the chicken gut. In a farm setting, flavophospholipol could have the potential to reduce the transmission of plasmid-mediated AMR between animals and have a positive effect in minimizing the risk of AMR transmission to humans through both direct contact and foodborne routes. There was insufficient evidence that flavophospholipol in-feed alone or with subtherapeutic levels of ampicillin had any plasmid-curing effect. Flavophospholipol has no analogue used for human therapy. This advantage coupled with the results from this study that flavophospholipol has anti-conjugative properties make it an attractive feed additive. It may be necessary to review the dose limit to consider maximizing the effect of flavophospholipol in reducing the acquisition of AMR.

**Acknowledgements**

Authors express appreciation to personnel of Infectious Disease Molecular Epidemiology Laboratory, College of Veterinary Medicine, The Ohio State University, USA.

---

### Table 9. Proportions and odds of ceftiofur-resistant transconjugants in treatment groups 6–8 versus control group 5, accounting for cage clustering

| Timepoint | Treatment | R− | R+ | % R+ | OR (95% CI) | Bonferroni corrected P-value |
|-----------|-----------|----|----|------|-------------|-----------------------------|
| 4 days p.i. | 5. Control | 82 | 0  | 0.0  | reference   | –                           |
|           | 6. Flavo-10 ppm + AMP | 79 | 13 | 14.1 | 18.57 (3.01 to ∞) | 0.0027 (exact) |
|           | 7. Flavo-64 ppm | 89 | 1  | 1.1  | 0.95 (0.15 to ∞) | 1.000 (exact) |
|           | 8. Flavo-64 ppm + AMP | 97 | 0  | 0.0  | –           | –                           |
| 11 days p.i. | 5. Control | 73 | 17 | 23.9 | reference   | –                           |
|           | 6. Flavo-10 ppm + AMP | 78 | 17 | 22.7 | 2.27 (0.58–8.98) | 1.000 |
|           | 7. Flavo-64 ppm | 70 | 6  | 9.0  | 0.89 (0.22–3.56) | 1.000 |
|           | 8. Flavo-64 ppm + AMP | 98 | 0  | 0.0  | 0.43 (0.0–81)  | 0.0576 (exact) |
| 20 days p.i. | 5. Control | 62 | 18 | 22.5 | reference   | –                           |
|           | 6. Flavo-10 ppm + AMP | 73 | 18 | 19.8 | 0.85 (0.19–3.87) | 1.000 |
|           | 7. Flavo-64 ppm | 85 | 1  | 1.2  | 0.041 (0.0048–0.35) | 0.027 |
|           | 8. Flavo-64 ppm + AMP | 90 | 0  | 0.0  | 0.30 (0.0–55)  | <0.0001 (exact) |
| 32 days p.i. | 5. Control | 63 | 21 | 32.5 | reference   | –                           |
|           | 6. Flavo-10 ppm + AMP | 81 | 17 | 21.1 | 0.63 (0.13–3.09) | 1.000 |
|           | 7. Flavo-64 ppm | 91 | 2  | 2.2  | 0.07 (0.0087–0.50) | 0.027 |
|           | 8. Flavo-64 ppm + AMP | 94 | 0  | 0.0  | 0.28 (0.0–51)  | <0.0001 (exact) |

R, ceftiofur resistance; AMP, ampicillin. Robust SEs, accounting for cage clustering were used for timepoints 4, 11 and 20 days post inoculation (p.i.) A Bonferroni correction of 9 was used for timepoints 4, 11 and 20 days p.i., to control errors introduced in pair-wise tests comparing swab results in 3 treatment groups and control, and a Bonferroni correction of 3 was applied at timepoint 32 days p.i., to control errors introduced in pair-wise tests comparing caecum results in 3 treatment groups and control. Exact logistic regression models were used where (exact) is indicated.

**Funding**

This work was supported by Huvepharma Ltd.

**Transparency declarations**

None to declare.

**References**

1. Pfaller MA. Flavophospholipol use in animals: Positive implications for antimicrobial resistance based on its microbiologic properties. *Diagn Microbiol Infect Dis* 2006; 56: 115–21.
2. Butaye P, Devries LA, Haesebrouck F. Influence of different medium components on the *in vitro* activity of the growth-promoting antibiotic flavomycin against enterococci. *J Antimicrob Chemother* 2000; 46: 115–21.
3. van den Bogaard AE, Hazen M, Hoyer M et al. Effects of flavophospholipol on Resistance in Fecal *Escherichia coli* and Enterococci of Fattening P. *Antimicrob Agents Chemother* 2002; 46: 110–8.
4. Riedl S, Ohlsen K, Werner G et al. Impact of flavophospholipol and vancomycin on conjugal transfer of vancomycin resistance plasmids. *Antimicrob Agents Chemother* 2000; 44: 3189–92.
5. Dealy J, Moeller MW. Influence of bambermycin on salmonella infection and antibiotic resistance in calves. *J Anim Sci* 1977; 44: 734–8.
6. Dorr PM, Gebreyes WA. Flavophospholipol: Effect on multi-drug resistant *Salmonella enterica* serovar Typhimurium in swine. *J Swine Heal Prod* 2009; 17: 308–17.
7. Poole TL, McReynolds JL, Edrington TS et al. Effect of flavophospholipol on conjugation frequency between *Escherichia coli* donor and recipient pairs in vitro and in the chicken gastrointestinal tract. *J Antimicrob Chemother* 2006; 58: 359–66.
8 Majowicz SE, Musto J, Scallan E et al. The global burden of nontyphoidal salmonella gastroenteritis. *Clin Infect Dis* 2010; 50: 882–9.
9 Scallan E, Hoekstra RM, Angulo FJ et al. Foodborne illness acquired in the United States-major pathogens. *Emerg Infect Dis* 2011; 17: 7–15.
10 Alcaine SD, Warnick LD, Wiedmann M. Antimicrobial resistance in nontypoidal Salmonella. *J Food Prot* 2007; 70: 780–90.
11 Varma JK, Mølbak K, Barrett TJ et al. Antimicrobial-resistant nontyphoidal salmonella is associated with excess bloodstream infections and hospitalizations. *JI Infect Dis* 2005; 187: 251–9.
12 Rashmi S, Chaman LS, Bhuvneshwar K. Antibacterial resistance: current problems and possible solutions. *Indian J Med Sci* 2005; 59: 120–9.
13 Leverstein-van Hall MA, M Blok HE, T Donders AR et al. Multidrug resistance among Enterobacteriaceae is strongly associated with the presence of integrons and is independent of species or isolate origin. *JI Infect Dis* 2003; 187: 251–9.
14 de Barros R, Vieira SL, Favero A et al. Reassessing flavophospholipol effects on broiler performance. *Rev Bras Zootec* 2012; 41: 2458–62.
15 Gebreyes WA, Altier C. Molecular characterization of multidrug-resistant Salmonella enterica subsp. enterica serovar Typhimurium isolates from swine. *J Clin Microbial* 2002; 40: 2813–22.
16 Carrique-Mas JJ, Davies RH. Sampling and bacteriological detection of Salmonella in poultry and poultry premises: a review. *Rev Sci Tech* 2008; 27: 665.
17 Bauer AW. Antibiotic susceptibility testing by a standardized single disc method. *Am J Clin Pathol* 1966; 45: 149–58.
18 Overdevest I, Willemsen I, Rijnsburger M et al. Extended-spectrum β-lactamase genes of *Escherichia coli* in chicken meat and humans, The Netherlands. *Emerg Infect Dis* 2011; 17: 1216–22.
19 Hemming K, Marsh J. A menu-driven facility for sample-size calculations in cluster randomized controlled trials. *Stata J* 2013; 13: 114–35.
20 Alali WQ, Thakur S, Berghaus RD et al. Prevalence and distribution of Salmonella in organic and conventional broiler poultry farms. *Foodborne Pathog Dis* 2010; 7: 1363–71.
21 Procter TD, Pearl DL, Finley RL et al. A cross-sectional study examining the prevalence and risk factors for anti-microbial-resistant generic *Escherichia coli* in domestic dogs that frequent dog parks in three cities in South-Western Ontario, Canada. *Zoonoses Public Health* 2014; 61: 250–9.
22 Cameron A, Miller D. A practitioner’s guide to cluster-robust inference. *J Hum Resour* 2015; 50: 317–72.
23 Wu C, Wang Y, Shi X et al. Rapid rise of the ESBL and mcr-1 genes in *Escherichia coli* of chicken origin in China, 2008-2014. *Emerg Microbes Infect* 2018; 7: 30.
24 Hao H, Cheng G, Iqbal Z et al. Benefits and risks of antimicrobial use in food-producing animals. *Front Microbiol* 2014; 5: 288.
25 Khachatourians GG. Agricultural use of antibiotics and the evolution and transfer of antibiotic-resistant bacteria. *CMAJ* 1998; 159: 1129–36.
26 Wasyl D, Hoszowski A, Zającz M. Prevalence and characterisation of quinolone resistance mechanisms in *Salmonella* spp. *Vet Microbiol* 2014; 171: 307–14.